- Home
- AGEN vs CEE Comparison
AGEN vs CEE Comparison
Compare AGEN & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGEN | CEE |
|---|---|---|
| Founded | 1994 | 1990 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 101.1M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | CEE |
|---|---|---|
| Price | $3.12 | $17.81 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 639.2K | 22.0K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.86% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,829,000.00 | N/A |
| Revenue This Year | $67.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $7.80 |
| 52 Week High | $7.34 | $10.32 |
Technical Indicators
Market Signals| Indicator | AGEN | CEE |
|---|---|---|
| Relative Strength Index (RSI) | 26.40 | 62.97 |
| Support Level | $3.01 | $16.90 |
| Resistance Level | $4.00 | $18.46 |
| Average True Range (ATR) | 0.25 | 0.58 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 11.26 | 66.32 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.